Williams Cancer Institute

Menu
Menu
Lymphoma · Interventional immuno-oncology

When CAR-T loses its target, we re-engage your immune system against the rest.

For lymphoma that has returned after even the newest treatments — we treat an accessible lymph node directly to re-engage your immune system against the rest.

Personalized

Minimally invasive

Immune-activating

Outpatient

In plain terms

What we do, in three paragraphs.

Lymphoma is unusually well suited to our approach because lymph nodes are easy to reach with a needle. We treat the tumor directly: ablation plus intratumoral immunotherapy injected straight into an accessible node or mass — aimed especially at lymphomas that have come back after the newest cell-based treatments.
Powerful therapies like CAR-T and bispecific antibodies can fail through antigen escape — the cancer simply stops displaying the marker those treatments target. Our approach sidesteps that: injecting immunotherapy directly into a node re-engages your immune system against other tumor signals — a personalized vaccine aiming for a body-wide (abscopal) response.
Intratumoral CpG in lymphoma has real research precedent, though adding certain agonists hasn’t improved outcomes in trials so far — we’re honest that this is an evolving approach. We coordinate with your hematology and cell-therapy teams; most patients finish in about a week. Results vary.

One needle, one session: ablation plus immunotherapy delivered where the cancer lives.

AblationVax: the treated tumor teaches your immune system to attack cancer body-wide.

Real outcomes

Post-CAR-T, post-bispecific disease.

Recurrent disease after CAR-T and bispecifics is biologically distinct — exhausted CAR-T product, downregulated CD19/CD20, antigen escape. Our approach: intratumoral immune amplification at accessible nodal or extranodal disease.

Individual results vary. These outcomes represent specific patient cases and are not guaranteed for all patients.

Where our approach fits

Treatment options by stage.

Find your diagnosis below to see what standard care offers, where we add to it, and what role our approach plays.

First-line

Standard care
R-CHOP, Pola-R-CHP, ABVD, BR for indolent disease.
What we add
Our approach is rarely first-line.
Standard care first

First relapse

Standard care
Salvage chemo + ASCT, CAR-T, bispecifics.
What we add
Our approach is rarely first-line at this step.
Standard care first

Our primary focus

Post-CAR-T / post-bispecific

Standard care
Limited remaining options after progression.
What we add
Intratumoral immune amplification + ablation.

CAR-T failure modes include CD19 loss and product exhaustion — we engage host T-cell responses independent of the CAR-T product.

Re-engagement

Oligoprogressive

Standard care
A few growing sites on systemic therapy.
What we add
Local control + intratumoral immune amplification.
Local + systemic strategy

Beyond ablation alone

Destroy the tumor, then teach your immune system to finish the job.

Standard approaches
Our approach — AblationVax
R-CHOP / Pola-R-CHP → CAR-T → bispecific.
Ablation + intratumoral immunotherapy at post-CAR-T / post-bispecific progression, designed for antigen-escape disease.

IV checkpoint blockade in Hodgkin: effective but limited durability.
Delivered directly into the tumor rather than through the bloodstream. The aim is to concentrate treatment at the tumor site and limit whole-body exposure.

No established option after CAR-T + bispecific exhaustion.
Multi-agent intratumoral cocktails as next-line consideration.

Why this approach for lymphoma?

Treats accessible nodes and masses

Lymphoma’s nodal anatomy is highly accessible to image-guided procedures.

Converts antigen-escape disease into hot targets

When CD19 / CD20 are lost, intratumoral immunotherapy is under investigation to re-engage responses against alternate tumor antigens.

Aims for systemic response

The investigational goal is to determine whether treating one lymph node can stimulate immune activity across the disease — the approach known as in-situ vaccination.

Lymphoma-specific breakthrough

Intratumoral immune amplification in antigen-loss disease.

“Lymphoma is the most accessible pathology for image-guided ablation and intratumoral injection. We use that accessibility to amplify immunity locally — particularly where CAR-T or bispecific therapy lost effectiveness through antigen escape.”

— Dr. Jason R. Williams

TLR9 + costimulation in accessible nodes

Intratumoral CpG in lymphoma has substantial research precedent (Stanford in-situ vaccination work). Caveat: costimulatory agonist additions have not improved trial outcomes to date.

Re-engagement after antigen loss

When CD19 or CD20 escape limits CAR-T or bispecifics, amplification at residual disease can engage T-cell responses against alternate antigens.

The combination

CpG, OX40 / CD40 agonists, and checkpoint inhibitors delivered intratumorally for patients beyond available cell-therapy lines.

“Lymphoma was one of the first contexts where intratumoral immunotherapy showed real systemic responses. We extend that framework toward antigen-escape and immune-resistant disease.” — Dr. Williams

Beyond the procedure: whole-patient support.

We optimize your entire system for the best possible response — and coordinate with the team you already have.

Gut microbiome optimization

Diet, probiotics, and related therapies to support a stronger immunotherapy response.

Off-label protocols

Strategic use of repurposed medications to enhance immune response.

Personalized cocktails

Multi-agent immunotherapy tailored to your specific cancer.

Oncologist coordination

We work alongside your current chemo and radiation team.

What to expect

Your path to treatment.

1

Case review

We review your PET-CT and biopsy reports (subtype, CD19/CD20/CD30 status, MYC/BCL2/BCL6).

2

Protocol design

A personalized cocktail tuned to subtype, prior CAR-T / bispecific, and immune profile.

3

Procedure week

Image-guided ablation + intratumoral immunotherapy at an accessible nodal site. Outpatient.

4

Follow-up

PET-CT at 6–8 weeks, coordination with your home hematology team.

Procedure ~1 hour

Recovery ~2 hours

All outpatient

Is this right for you?

You may be a candidate if:

✓Relapsed / refractory DLBCL post-CAR-T
✓Progression after CD20×CD3 bispecifics
✓Follicular lymphoma post-CAR-T or post-bispecific
✓Hodgkin lymphoma after checkpoint blockade and brentuximab
✓Antigen-escape disease (CD19 / CD20 / CD30 loss)

It may not be suitable if:

—CRS / ICANS recovery still active
—Active severe infection
—Uncorrectable bleeding disorders
—Very poor performance status (ECOG ≥ 3)
—Bone marrow failure without a supportive plan

Each case is individually evaluated by Dr. Williams’ team.

Track record

Innovation for lymphoma.

2014

Multi-agent intratumoral protocols

The AblationVax concept.

2015

In-situ vaccination precedent grows

Intratumoral TLR9 approaches in lymphoma establish the systemic-response principle.

Now

Intratumoral CpG / OX40 / CD40 / checkpoint protocols

For post-CAR-T and post-bispecific lymphoma.

Ready to move forward?

There is more ahead. Take the next step with confidence.

Complimentary evaluation.

Dr. Williams’ team will personally review your case and imaging — no cost, no obligation.

Or email info@williamscancerinstitute.com

Beverly Hills · San Jose del Cabo · Mexico City — most patients complete treatment in one week

(theme footer continues — owned by Astra)

Menu

Email Signup